Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of SURFAXIN® (Lucinactant), in Very Low Birth Weight (VLBW) Infants at Risk for Developing Bronchopulmonary Dysplasia

NCT00215540 is registered in ClinicalTrials.gov with Windtree Therapeutics as lead sponsor.

NCT NCT00215540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00215540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of SURFAXIN® (Lucinactant), in Very Low Birth Weight (VLBW) Infants at Risk for Developing Bronchopulmonary Dysplasia
Lead sponsor
Windtree Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2005
Completion date
July 31, 2006
Enrollment
136 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bronchopulmonary dysplasia, premature birth, respiratory distress syndrome, newborn